Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases
Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for a digital oral presentation at the 18th Congress of ECCO - Inflammatory Bowel Diseases, hosted by the European Crohn’s and Colitis Organisation from March 1-4, 2023, in Copenhagen, Denmark.